Summary
Acute Ischemic Stroke (AIS) represents 85% of strokes and is the 2nd leading cause of death and the leading cause of disability worldwide. Today, AIS patient management lies on imaging tools (multimodal CT/MRI) and scores to select patients for Endovascular treatment (EVT) – the gold standard. Still, its efficacy is limited to 46% due to the lack of tools to guide decision-making. BraiN20® is a non-invasive medical device class IIb that provides real-time monitoring of AIS patients’ brain viability, thereby predicting who will benefit from EVT. Time is Brain has the exclusive right to the IPR of a neurophysiological biomarker: N20, a SEP and surrogate of cerebral blood flow. TiB aims to implement the clinical trials to validate BraiN20®, acquire CE-Mark and FDA clearance, and bring it to market. By providing real-time and continuous monitoring of brain viability, BraiN20® will accelerate stroke management and predict EVT outcome and offer tailored care for each patient.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190126352 |
| Start date: | 01-05-2023 |
| End date: | 30-04-2026 |
| Total budget - Public funding: | 5 150 878,25 Euro - 2 500 000,00 Euro |
Cordis data
Original description
Acute Ischemic Stroke (AIS) represents 85% of strokes and is the 2nd leading cause of death and the leading cause of disability worldwide. Today, AIS patient management lies on imaging tools (multimodal CT/MRI) and scores to select patients for Endovascular treatment (EVT) – the gold standard. Still, its efficacy is limited to 46% due to the lack of tools to guide decision-making. BraiN20® is a non-invasive medical device class IIb that provides real-time monitoring of AIS patients’ brain viability, thereby predicting who will benefit from EVT. Time is Brain has the exclusive right to the IPR of a neurophysiological biomarker: N20, a SEP and surrogate of cerebral blood flow. TiB aims to implement the clinical trials to validate BraiN20®, acquire CE-Mark and FDA clearance, and bring it to market. By providing real-time and continuous monitoring of brain viability, BraiN20® will accelerate stroke management and predict EVT outcome and offer tailored care for each patient.Status
SIGNEDCall topic
HORIZON-EIC-2022-ACCELERATOROPEN-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
